This article has been updated with additional details on the coverage criteria of the LCD.

NEW YORK (GenomeWeb) – Genomic Health today announced that Medicare contractor Palmetto GBA has issued a draft local coverage determination for its Oncotype DX prostate cancer test.

The draft LCD recommends coverage of the test for qualified Medicare patients "to help determine which patients with early-stage, needle biopsy proven prostate cancer can be conservatively managed rather than treated with definitive surgery or radiation therapy."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.